About Eikonoklastes Therapeutics
Eikonoklastes Therapeutics is a private company based in Cincinnati, Ohio. It has reported $27,531,860 raised in six offerings on Form D since March 2020. Its chief executive is Bruce Halpryn.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 14, 2025 | Jul 29, 2025amended Oct 6, 2026 | $16,055,106of $18.6M target | 15 | $1.0M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 12, 2024 | Jun 25, 2024 | $2,400,000of $8.0M target | 3 | $800K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Nov 9, 2023 | Nov 27, 2023 | $2,000,000of $15.0M target | 1 | $2.0M | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Dec 31, 2021 | Jan 13, 2022 | $2,800,000of $7.0M target | 1 | $2.8M | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Apr 22, 2021 | May 6, 2021 | $3,176,754of $7.0M target | 9 | $352K | EquityRule 506(b) | Form D ↗ |
| Feb 19, 2020 | Mar 5, 2020 | $1,100,000of $4.0M target | 2 | $550K | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, six offerings | $27,531,860 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Eikonoklastes Therapeutics's Form D filed Oct 6, 2026.
SL
KM
Kenneth Morand
Partner, CincyTech and director
TF
RJ
Robert Johnson
CEO, Kesmalea Therapeutics and director
JN
Joseph Nolan
CEO, Jaguar Gene Therapy and director
Earlier filings also listed Neel Patel (director, last listed Jun 2024) and Meyer Frucher (director, last listed Jun 2024).